Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Ritlecitinib can help about 14,000 people with severe hair loss.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

Rash from EGFRI treatment can indicate both side effects and treatment effectiveness.

Selaginella doederleinii extract shows potential for cervical cancer treatment but needs more research.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

The combination therapy effectively treats infertility in PCOS without major side effects.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

EGFR inhibitors can cause unusual localized hair growth.

Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.